AstraZeneca Plc (NYSE: AZN) CEO Pascal Soriot said during a conference call with investors Wednesday that a person experiencing symptoms related to a rare neurological disorder caused its global COVID-19 vaccine trials to pause, Stat reported. What Happened: Soriot revealed that the trial participant, a woman in the United Kingdom, suffered symptoms consistent with a spinal inflammatory disorder called transverse myelitis, according to Stat.The diagnosis wasn’t confirmed and the woman could to be discharged from the hospital as soon as Wednesday, according to the executive.A board overseeing safety and data components of the trial reportedly confirmed that the participant was …read more
Source:: Yahoo Finance
